iBio, Inc. 

iBio, Inc. (NYSE: IBIO) is a biopharmaceutical developer and the inventor of the sustainable FastPharming Manufacturing System. Using licensed and owned technologies, the company develops novel treatments to prevent fibrotic disorders, malignancies, and infectious diseases. 

Key Highlights: 

• The company reported a significant decline in revenues to USD 211 thousand in Q1FY22 (ended September 30, 2021) compared to USD 410 thousand in Q1FY21. 
• IBIO generated 100%of its revenue from three clients in Q1FY22, with two customers accounting for 81%of revenue; losing any customer could negatively influence the company's topline in the future. 
• IBIO reported an increase in net losses to USD 8.94 million in Q1FY22 from USD 7.53 million in Q1FY21. 
• In Q1FY22, the company's average receivable days were 2,336 days, compared to the industry median of 60.5 days. 
• The stock is now trading below its key short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 36.66, indicating a bearish trend. 

• Stock is leaning towards the lower band of the 52-week range of USD 0.39 to USD 2.83. 
• IBIO stock price has fallen 66.38and 72.24% inthe past six and nine months, respectively. 

Three-Year Technical Price Chart (as of February 10, 2022; 12:33 PM ET). Analysis by Kalkine Group 

Conclusion: Considering the bottom-line stress, uncertain outlook, insignificant topline, reliance on specific customers, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.4136, down 1.52% as of February 10, 2022, at 12:33 PM ET. 

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine. 

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it. 

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product. 

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people. 

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.  

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.  

Please also read our Terms & Conditions and Financial Services Guide for further information. 

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures. 

 
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.